

ATHENE II: Alzheimer’s Disease THErapy with NEuroaid II

Christopher Chen Li Hsian^a, on behalf of the ATHENE II Investigators

^a Memory Aging and Cognition Centre, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

- First biomarker-enriched confirmatory trial of MLC901 in Alzheimer's disease.
- Evaluates cognitive and functional outcomes over 12 months.
- Integrated clinical and biomarker assessments will evaluate MLC901 treatment effects.

INTRODUCTION	METHODS	RESULTS	CONCLUSIONS	REFERENCES
Alzheimer’s disease remains a major global health challenge, with limited safe and accessible options to slow disease progression. MLC901 (NeuroAiD™II) is a multimodal therapy with neuroprotective and neurorestorative properties^{1,2,3}. Building on encouraging ATHENE⁴ findings, ATHENE II is a biomarker-enriched confirmatory trial evaluating MLC901 in mild-to-moderate Alzheimer’s disease.	• International, multicentre, randomized, double-blind, placebo-controlled Phase III trial (N=350). • Mild-to-moderate Alzheimer’s disease with elevated plasma p-tau217. • Randomized 1:1 to MLC901 or placebo for 12 months. • Primary endpoint: ADAS-Cog11 • Secondary endpoints: CDR-SB, CDR Global Score, ADCS-ADL, NPI, and safety. • Exploratory endpoints: Plasma p-tau217, NfL, GFAP.	ATHENE II is a global, biomarker-enriched trial evaluating MLC901 in 350 patients with mild-to-moderate Alzheimer’s disease. The study incorporates plasma biomarkers for participant selection and longitudinal assessment alongside established clinical outcomes. At the time of poster presentation, patient recruitment had not yet commenced.	ATHENE II is a biomarker-enriched Phase III trial evaluating MLC901 in biomarker-confirmed Alzheimer's disease. Clinical and plasma biomarker assessments will provide a comprehensive evaluation of treatment effects over 12 months.	1.Heurteaux C, Gandin C, Borsotto M, Widmann C, Brau F, et al. Neuroprotective and neuroproliferative activities of NeuroAid (MLC601, MLC901), a Chinese medicine, in vitro and in vivo. Neuropharmacology.2010 Jun;58(7):987-1001. doi:10.1016/j.neuropharm.2010.01.001. 2.Heurteaux C, Widmann C, Moha ou Maati H, Quintard H, Gandin C, et al. NeuroAiD: properties for neuroprotection and neurorepair. Cerebrovasc Dis. 2013;35 Suppl 1:1-7 doi:10.1159/000346228. 3. Quintard H, Borsotto M, Veyssiere J, Gandin C, Labbal F, et al. MLC901, a traditional Chinese medicine protects the brain against global ischemia. Neuropharmacology. 2011 Sep;61(4):622-31. doi: 10.1016/j.neuropharm.2011.05.003. 4. Chen CLH, Lu Q, Moorakonda RB, Kandiah N, Tan BY, Villaraza SG, et al. Alzheimer's Disease THErapy With NEuroaid (ATHENE): A Randomized Double-Blind Delayed-Start Trial. J Am Med Dir Assoc. 2022 Mar;23(3):379-386.e3. doi:10.1016/j.jamda.2021.10.018. CONTACT Email: phccclh@nus.edu.sg  ALZHEIMER'S ASSOCIATION AAIC 